Analyst Price Target is $32.80
▲ +1,097.08% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Syros Pharmaceuticals in the last 3 months. The average price target is $32.80, with a high forecast of $100.00 and a low forecast of $13.00. The average price target represents a 1,097.08% upside from the last price of $2.74.
Current Consensus is
The current consensus among 5 contributing investment analysts is to buy stock in Syros Pharmaceuticals. This Buy consensus rating has held steady for over two years.
Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425, SY-2101, and SY-5609. The company was founded by Richard A. Young, Nathanael S. Gray, and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.